Table 4.

Logistic regression assessing for association of TNFi use and elevated laboratory values

Laboratory variables (cut-off values)	Number of observations	Odds ratio (95% CI)	p-value	AIC	BIC
NLR (3.669)	779	0.172 (0.100–0.295)	<0.001	465.386	502.650
PLR (242.466)	727	0.073 (0.024–0.219)	<0.001	168.163	204.874
ESR (22.000 mm/Hr)	724	0.319 (0.221–0.463)	<0.001	803.004	839.682
CRP (1.980 mg/dL)	688	0.407 (0.268–0.618)	<0.001	636.908	673.178
NLR (+ ESR)	672	0.159 (0.085–0.299)	<0.001	373.007	413.599
NLR (+ CRP)	602	0.197 (0.107–0.359)	<0.001	373.807	413.409
PLR (+ ESR)	263	0.059 (0.015–0.237)	<0.001	128.216	156.793
PLR (+ CRP)	146	0.084 (0.024–0.296)	<0.001	120.333	144.202

Controlled for race, age, disease duration, Charlson Comorbidity index, alcohol use, marital status.

The final models (+ ESR and + CRP) tested for associations of PLR and sacroiliitis after included either ESR or CRP in the model.

TNFi, tumor necrosis factor inhibitor; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CI, confidence interval; AIC, Akaike Information Criteria; BIC, Bayesian Information Criteria; mm/Hr, millimeters per hour; mg/dL, milligrams per deciliter